ENGLEWOOD, Colo., May 3, 2016 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today the acceptance of three new publications in peer-reviewed scientific forums that report mechanisms of action (MOA) of Ampion™.
Two poster presentations on Ampion™ will be presented at the 75th annual meeting of the American Association for the Surgery of Trauma (AAST) to be held in Waikoloa, HI, in September 2016. The two abstracts describe MOA of Ampion™ in cell cultures of osteoarthritic synoviocytes (fibroblast-like cells that line the synovial membrane) and are believed to be important in the pathophysiology of osteoarthritis.
- “The Low Molecular Weight Fraction Of Human Serum Albumin As A Potential Therapeutic For Inflammatory Conditions Due To Its Role In The COX2 Pathway.” Elizabeth Frederick, PhD; Melissa Hausburg, PhD; Leonard Rael, MS; Gregory Thomas, BS; Matthew Carrick, MD; Charles W. Mains, MD; Denetta S. Slone, MD; David Bar-Or, MD
- “The Low Molecular Weight Fraction Of Human Serum Albumin (HSA) Inhibits NfκB Signaling.” Melissa Hausburg, PhD; Elizabeth Frederick, PhD; Gregory Thomas, BS; Leonard Rael, MS; Matthew Carrick, MD; Charles W. Mains, MD; Denetta S. Slone, MD, David Bar-Or, MD.
The third publication is titled:
- The Low Molecular Weight Fraction of Human Serum Albumin Up-regulates Production of 15d-PGJ(2) in Peripheral Blood Mononuclear Cells.” Gregory Thomas, BS; Leonard Rael, MS; Melissa Hausburg, PhD; Elizabeth Frederick, PhD; Charles Mains, MD; Denetta Slone, MD; Matthew Carrick, MD; David, Bar-Or, MD. This manuscript was published on April 16, 2016 in the Biochemical and Biophysical Research Communications
Dr. David Bar-Or, Ampio’s Chief Science Officer, noted “This manuscript reports Ampion™ up-regulates an important prostaglandin molecule (15d-PGJ2) associated with healing and resolution of inflammation in peripheral blood monocytes. These three publications in peer reviewed scientific forums further validate the scientific rationale for the use of the low molecular weight fraction of human serum albumin (Ampion™) in treating inflammatory conditions such as osteoarthritis. Several other scientific publications are in progress”.
Osteoarthritis (OA) is a progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone. The incidence of developing osteoarthritis of the knee over a lifetime is approximately 45%. As this disease is associated with age, obesity and diabetes this number will continue to grow. Certain risk factors in conjunction with natural wear and tear lead to the breakdown of cartilage. Osteoarthritis is caused by inflammation of the soft tissue and bony structures of the joint, which worsens over time and leads to progressive thinning of articular cartilage. Other symptoms include narrowing of the joint space, synovial membrane thickening, osteophyte formation and increased density of subchondral bone.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Forward Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s scientific presentations on our Ampion™ product. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Gregory A. Gould
Chief Financial Officer
Phone: (720) 437-6500
(1) Burden of Major Musculoskeletal Conditions; Woolf, Pfleger; Bulletin of the World Health Organization